Leslie Meltzer

Leslie Meltzer, PhD, currently serves as the Chief Research & Development Officer at Apellis Pharmaceuticals, a position held since August 2025. Prior experience includes serving as Chief Medical Officer at Orchard Therapeutics from June 2018 to August 2025, where significant achievements included securing FDA approval for LENMELDY (atidarsagene autotemcel) for early-onset metachromatic leukodystrophy in March 2024 and leading the EU launch of Libmeldy in December 2020. Additional roles at Orchard involved restructuring clinical operations and establishing a global diagnostics function. Previous positions include Vice President at Keryx Biopharmaceuticals, where Auryxia was successfully launched, and various roles at Biogen, including Senior Director of Medical Affairs for Hemophilia. Leslie Meltzer holds a PhD in Neuroscience from Stanford University and a B.S. in Biology, Neuroscience from Brandeis University.